Abstract:Abstract Background Despite advancements, understanding the tissue pharmacokinetics of Anti-tumour necrosis factor alpha monoclonal antibodies (aTNF) and addressing cases of primary non-response, secondary loss of response, and unexplained treatment failures in some patients pose ongoing challenges. The aim of this study was to investigate factors associated with intestinal tissue levels of aTNF, anti-drug antibodies and cytokines in paediatric patients with Crohn's Disease (CD). Methods A prospective study of paediatric CD patients treated with aTNF, who underwent ileocecal resection or colonoscopy between June 2020 and January 2023 was performed. Tissue drug levels of aTNF, anti-drug antibodies and pro-inflammatory cytokines ((TNF alpha (TNF-α), interleukin-17 (IL-17), interleukin-1 beta (IL-1β), interferon gamma (IFN-γ)) were analysed in tissue culture supernatant using ELISA. Logistic regression estimated odds ratios (OR) adjusted for potential confounding from disease localization, way of sampling, presence of inflammation, and type of anti TNF (aOR). Results Twenty-seven CD patients (18 females, 66.7%) with a median disease duration of 50 (Interquartile range [IQR] 23 – 69) months were analysed. Fourteen (52%) received adalimumab (ADA), thirteen (48%) received infliximab (IFX), with a median aTNF therapy duration of 17 (IQR 4.5 – 41.5) months. Tissue aTNF detection was 100% in ADA-treated and 81.8% in IFX-treated patients. A positive association between intestinal inflammation and the level of free aTNF in tissue was observed (aOR=3.03, 95% CI=0.82-5.29). The ratio of aTNF level in tissue to serum was higher in the inflamed tissue (aOR=0.21, 95% CI=0.039-0.38). Despite an adequate level of aTNF in the serum, no measurable level was detected in the tissue in 13 patients. When comparing anti-drug antibodies levels in serum and tissue, we found a notable discrepancy, with 19 patients having undetectable serum levels, while tissue levels were measurable. We found higher tissue IL-17 levels in patients who had been treated with aTNF therapy for a longer period (aOR=0.15, 95% CI=0.031-0.274), independent of disease duration and patient age. An association was found between the level of IFN-γ and the duration of follow-up, as well as with the duration of aTNF administration. However, it was not possible to determine which of these associations is responsible for this relationship. Conclusion Our study highlights significantly elevated free drug levels in inflammatory tissue compared to non-inflammatory tissue. Our findings also align with recent insights linking aTNF failure to upregulation of mucosal IL17, providing a possible molecular rationale for improved treatment response with treatment targeting the IL-23 receptor after aTNF treatment failure.

Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

Indicators of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy in Patients from China with Inflammatory Bowel Disease: Results from the EXPLORE Study

Progression of Crohn's Disease in Newly Diagnosed Patients: Results from an Observational Study Using US Claims Data

P502 Different Presentation of Tuberculosis Associated with Anti-Tnf Therapy among Patients with Inflammatory Bowel Disease in Endemic Area: Observation from China

P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

Anti-TNF-α Agents in the Treatment of Crohn's Disease: A Systematic Review

Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD)

Risk of Tuberculosis and Hepatitis B Reactivation in Patients with Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.

Biological agents in the treatment of Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC3) study

P853 Factors associated with intestinal tissue levels of anti-TNF in pediatric patients with Crohn's Disease

Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease

Mo1918 – Can We Stop Anti-Tumour Necrosis Factor (ANTI-TNF) in Patients with Perianal Crohn’s Disease ? Results from a Population-Based Study

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study

P611 Relation between AntiTNF levels during the induction and clinical and radiological outcomes in perianal Crohn ́s disease

High Body Mass Index and Response to Anti-TNF Therapy in Pediatric Crohn Disease

Characterization of Clinical and Serologic Features of Crohnʼs Disease and Anti-TNFα Use in a Chinese Cohort

Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn's Disease Initiating Biologics With 3 Years of Follow-Up